NTX-472 / Nutcracker Therapeutics - LARVOL DELTA

Development of NTX-472, a formulated mRNA therapy targeting CD20, CD19, and CD47, for treatment of B-cell lymphoma. (ASCO 2024) - " To understand the advantages gained from multispecific molecules for B cell lymphoma, we designed a panel of molecules targeting CD20, CD19 and CD47 and compared them to monospecific anti-CD20, Rituximab, or anti-CD19, Tafasitamab. Here, we demonstrate the potency of NTX-472, a novel nanoparticle formulated mRNA therapeutic candidate encoding a multispecific protein targeting CD19, CD20, and CD47 that has increased specificity for tumor cells and has potential to enable broad efficacy while limiting hematotoxicity within a setting of increased tumor heterogeneity post-Rituximab treatment."

IO biomarker • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Nutcracker Therapeutics Demonstrates Enhanced Activity of B Cell Lymphoma Candidate NTX-472 at the 2024 ASCO Annual Meeting (Businesswire) - "Nutcracker Therapeutics, Inc...recently presented a poster on NTX-472, its new preclinical drug candidate for B cell lymphoma, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago....Nutcracker Therapeutics’ scientists then further studied NTX-472 in vivo, which showed rapid depletion of B cells with no detectable binding to red blood cells in cynomolgus monkeys."

Preclinical • Hematological Malignancies • Lymphoma • Oncology

Nutcracker Therapeutics to Unveil New Drug Candidate NTX-472 at ASCO 2024 and Participate in the Sachs Oncology Innovation Forum (Businesswire) - "Nutcracker Therapeutics, Inc....today announced it will introduce its new preclinical drug candidate, NTX-472, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago from May 31 to June 4....NTX-472 uses engineered mRNA-encoded proteins to simultaneously engage CD20, CD19, and CD47. Nutcracker Therapeutics is currently developing the candidate for the treatment of B cell lymphoma."

Preclinical • Hematological Malignancies • Lymphoma • Oncology